Featured Article

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Press Release
CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM
  • New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing...
Read More
Blog
The Hidden Inspection Risk in Your Medical and Safety Review Workflow
  • You have just been told an inspection is coming. Your team’s first reaction is not to...
Read More
Blog
Why Medical and Safety Review Is One of the Last Manual Workflows in Clinical Trials
  • It is Tuesday morning. You have a data cut from last night, three studies to review...
Read More
CluePoints RBQM Live25 On-Demand Recordings are now Available! Banner - ROI of RBQM, ICH E6(R3) in Practice, Future of AI